GRI Bio, Inc. (GRI)
GRI Bio, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
GRI Bio, Inc. (GRI) is a Biotechnology company based in US with a market capitalization of $135.6K. Free cash flow was negative at -$10.2M. This page tracks GRI's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 3 employees · IPO Apr 24, 2023
Valuation
Valuation & price
$2.03as of May 17, 2026· -96.8% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.02
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$135.6K
Market cap
—
Revenue growth (YoY)
-0.0%
Gross margin
-$10.2M
Free cash flow (USD)
-$8.2M
Net debt
Net cash position
1399.6%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is GRI Bio, Inc.'s market cap?
GRI Bio, Inc. (GRI) has a market capitalization of $135.6K.
What is GRI's P/E ratio?
A meaningful P/E ratio is not available for GRI — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is GRI's price-to-book (P/B) ratio?
GRI trades at 0.02 times book value per share.
Are insiders buying GRI stock?
SEC Form 4 filings show no open-market insider buys at GRI Bio, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.